Related by context. All words. (Click for frequent words.) 87 Patent Lawsuit 87 Patent Infringement Case 85 Patent Infringement Suit 83 Files Patent Infringement 83 Wins Patent Infringement 83 Patent Infringement Lawsuit Against 83 Patent Ruling 83 Patent Dispute 83 Patent Infringement Litigation 82 Patent Lawsuit Against 82 Patent Suit 81 Patent Infringement 79 Patent Suit Against 79 Receives Favorable Ruling 79 Nasdaq Delisting 79 Preliminary Injunction Against 79 Announces Dismissal 78 Settles Patent 78 Favorable Ruling 78 Infringement Case 78 Files Patent 77 Settle Patent 77 Receives Favorable 77 Infringement Suit 77 Patent Infringement Action 77 Patent Infringement Claim 77 Settle Patent Litigation 77 Patent Infringement Suit Against 77 Patent Infringement Claims 77 Antitrust Lawsuit 77 Announces Favorable 77 Wins Summary Judgment 76 Announces Favorable Ruling 76 Jury Verdict 76 Patent Infringement Lawsuits 76 Countersuit 76 Settles Litigation 75 Patent Suits 75 Vigorously Defend 75 Files Patent Infringement Suit 75 Settle Litigation 75 Infringes 75 Purported Class 75 Pending Litigation 75 Shareholder Lawsuit 75 Injunction Against 75 Patent Disputes 75 Gets Favorable 75 Announce Settlement 74 Infringed 74 Files Patent Infringement Lawsuit 74 Settles Patent Litigation 74 Antitrust Case 74 Patent Reexamination 73 Antitrust Suit 73 Derivative Lawsuit 73 Initiates Patent Infringement 73 Files Motion 73 Denies Motion 73 Settles Patent Infringement Lawsuit 73 Antitrust Lawsuit Against 73 Trademark Infringement Lawsuit 72 Settle Patent Dispute 72 Trademark Dispute 72 Unsolicited Proposal From 72 Receives Notification 72 Patent Spat 72 Patent Upheld 72 Claim Against 72 Shareholder Lawsuit Against 72 Patent Litigation 72 Permanent Injunction Against 72 Action Suit 72 Declaratory Judgment 72 Receives Subpoena 72 Shareholder Suits 71 Patent Validity 71 Settles Charges 71 Announce License Agreement 71 Shareholder Derivative 71 Shareholder Suit 71 Files Lawsuit 71 Arthritis Drug 71 Action Suit Against 71 Wins Dismissal 71 Pomerantz Law Firm 71 Trademark Infringement 71 Lawsuit Involving 71 Files Lawsuits 71 Settle Shareholder 71 Legal Dispute 71 Announces FDA Clearance 71 Files Countersuit Against 71 Non Infringement 71 Nasdaq Delisting Notice 71 Receives Patent 71 Q4 Profit Plunges 71 Dismiss Lawsuit 71 Files Suit 71 Q1 Loss Widens 71 Patents Upheld 71 Acacia Subsidiary 70 Patent Issued 70 Q2 Loss Narrows 70 HSR Waiting Period 70 Malpractice Suit 70 NASDAQ Delisting 70 Pending Acquisition 70 Antitrust Complaint 70 Confirms Validity 70 Lawsuit Alleging 70 False Advertising 70 Completes Tender Offer 70 Shareholder Lawsuits 70 Backdating Case 70 Announces Proposed Settlement 70 Complaint Filed 70 Complaint Against 70 Generic Version 70 Board Authorizes 70 Suit Filed 70 CFO Resigns 70 Antitrust Probe 70 Judge Tosses Out 70 Gets Favorable Ruling 70 Court Dismisses 70 Q4 Loss Narrows 70 Achieves Significant 69 Provides Update Regarding 69 Lawsuit Brought 69 Licensing Pact 69 Whistleblower Lawsuit 69 Board Unanimously Rejects 69 Issued Patent 69 Lawsuit Dismissed 69 Announce Early Termination 69 Narrows 4Q Loss 69 Q3 Loss Narrows 69 Announce Expiration 69 Inequitable Conduct 69 Trademark Lawsuit 69 Injunctive Relief 69 Copyright Infringement Case 69 Whistleblower Suit 69 Sign License Agreement 69 Files IND 69 Q4 Loss Widens 69 Taro Receives 69 Lowers Guidance 69 Files Voluntary 69 Kickback Case 69 4Q Loss Widens 69 Q2 Loss Widens 69 Q2 Adj 69 Explore Strategic Alternatives 69 Receives Positive 69 Sign Licensing Agreement 69 FDA Clears 69 Stockholders Reject 69 Plans Job Cuts 69 Files Patent Application 69 Provides Status 69 Announces Immediate Availability 69 Seeks Injunction 69 Regains Compliance 69 Q3 Loss Widens 69 Summary Judgment Order 68 Awarded Patent 68 Posts Wider Loss 68 Shareholder Claims 68 Court Invalidates 68 Amend Merger Agreement 68 Judge Nixes 68 Lawsuit Filed 68 Confirms Receipt 68 Reaches Settlement Agreement 68 Lawsuits Filed 68 Announces Licensing Agreement 68 Suit Vs 68 Files Petition 68 Commenced Against 68 Shareholder Investigation 68 Reduces Debt 68 Settles Fraud 68 Planned Acquisition 68 Action Lawsuit 68 Sign Definitive Agreement 68 Reminds Shareholders 68 Unsolicited Tender Offer 68 Announces Definitive Agreement 68 Shares Plummet 68 Extends Tender Offer 68 Suit Against 68 Restructures Debt 68 Jury Verdict Against 68 Shares Soar 68 Q1 Loss Narrows 68 Permanent Injunction 68 Fraud Suit 68 Action Lawsuits 68 Begins Shipment 68 Dismiss Case 68 Gets Subpoena 68 Settles Dispute 68 Complies With 68 Investigates Claims 68 Develop Next Generation 68 Reach Settlement Agreement 68 Posts 1Q Profit 68 Antitrust Settlement 68 Terminates Merger Agreement 68 LLP Investigates 68 Licenses Patents 68 Settles Patent Dispute 68 Terminate Agreement 68 Verdict Upheld 68 Suit Settled 68 Court Reverses 68 Terminate Merger Agreement 68 Derivative Action 68 Wins Approval 68 Discontinues 68 Announces Stockholder Approval 67 Restate Financials 67 Markman Hearing 67 Million Verdict 67 1Q Loss Widens 67 Receives NASDAQ 67 Licenses Novel 67 Proxy Contest 67 Receives CE Marking 67 Antitrust Suit Against 67 Lifts FY# Outlook 67 Previously Disclosed 67 Secures Patent 67 Issues Statement Regarding 67 Provides Shareholder 67 Exploring Strategic Alternatives 67 Completes Patient Enrollment 67 Settle Dispute Over 67 License Pact 67 Jointly Announce 67 Files Complaint 67 Counterclaims 67 Settle Antitrust 67 Epilepsy Drug 67 3Q Loss Widens 67 Protects Customers 67 Acquire Assets 67 Files Definitive Proxy 67 Settles Lawsuits 67 Successfully Defends 67 No. #-# Fed. 67 Rehearing En Banc 67 Investigation Relating 67 NASDAQ Listing Requirements 67 Strengthens Balance Sheet 67 Proxy Fight 67 Receives Milestone Payment 67 Gout Drug 67 Stock Soars 67 Posts 4Q Profit 67 Analyst Downgrade 67 Teva Provides Update 67 Achieves Milestone 67 Buyout Bid 67 Appeals Court Upholds 67 Stock Plunges 67 Receives Unsolicited 67 Receives Orphan Drug Designation 67 Claim Filed 67 Announce Licensing Agreement 67 CHMP Opinion 67 Enemy Combatant Case 67 Unveils Newest 67 Rehear 67 Develop Novel 67 Begins Tender Offer 67 Successfully Completes Tender Offer 67 Discrimination Case 67 Obtains Exclusive License 67 Lawsuit Challenging 67 Narrows Loss 67 Trademark Suit 67 Settle Lawsuits 67 Reach Settlement 67 Unsolicited Proposal 67 Files Antitrust Suit 67 Case Involving 67 Plans Buyback 67 Patent Infringement Complaint 67 Submits NDA 67 Submits Application 67 Provides Guidance 67 Case Thrown Out 67 Regains Full 67 Regains Compliance With 67 Milestone Payment 67 Q2 Profit Plunges 66 Receives Approvable Letter 66 Backs FY# Outlook 66 Introduces Enhanced 66 Posts 4Q Loss 66 Lawsuit Against 66 Reaffirms Outlook 66 Completes Enrollment 66 Files Provisional 66 Lawsuit Dismissed Against 66 Regains NASDAQ 66 Q2 Profit Plummets 66 Backs FY# View 66 Q1 Adj 66 Spears Conservatorship 66 Delays Filing 66 Receives Commitment 66 Patient Enrollment 66 Rehearing 66 Defamation Case 66 Obtains Exclusive Rights 66 Regains Nasdaq 66 Vioxx Suits 66 Suits Against 66 Defamation Lawsuit 66 Debuts Next Generation 66 Device Maker 66 Reports Receipt 66 Gets FDA Clearance 66 Files Lawsuit Against 66 Markman Ruling 66 Court Vacates 66 Accounting Errors 66 Expand Relationship 66 Share Repurchases 66 Evaluate Strategic Alternatives 66 Receives FDA Clearance 66 Extends Expiration Date 66 Amends Agreement 66 Settles Suit 66 Q4 Profit Drops 66 Extends Maturity 66 Analyst Upgrade 66 Posts 2Q 66 DVD Copying 66 Approve Merger 66 Court Nixes 66 Posts 2Q Profit 66 Antitrust Ruling 66 FDA Accepts 66 Clears Path 66 Reconfirms 66 Streamlines Operations 66 Q2 Profit Surges 66 Awarded Patents 66 Q4 Profit Surges 66 Misled Investors 66 Patent Covering 66 Vacates 66 Explores Strategic Alternatives 66 Attorneys Fees 66 Oral Argument 66 Announce Receipt 66 Guides Inline 66 Supreme Court Hears 66 Discrimination Lawsuit 66 KB Home Swings 66 Posts 3Q Profit 66 Patent Infringements 66 Immunomedics Announces 66 Licensing Deal 66 Lawsuit Settled 66 Announces Definitive Agreements 66 Signs Licensing Agreement 66 4Q Profit Surges 66 Files Amended 66 Regulatory Clearance 66 Justices Weigh 66 Biotech Firm 66 Reaffirms FY# Outlook 66 Judge Tosses 66 Announces Intent 66 Seeks Dismissal Of 66 Announces Early Termination 66 Announces Tentative Approval 66 Settlement Reached 66 FDA Panel Recommends 66 Ups Guidance 66 Suit Challenging 66 Settles Claim 66 Posts Wider 4Q Loss 66 Delivers Comprehensive 66 Rejects Request 66 Jumps Higher 66 Suit Dismissed 66 2Q Loss Widens 66 Q3 Adj 66 Patent Invalid 66 Ups Bid 66 Drug Coated Stent 66 Revises FY# Outlook 66 Settle Suits 66 Judge Throws Out 66 Takeover Speculation 66 Hostile Bid 66 Narrows Guidance 65 Unveils Groundbreaking 65 Destroyed Evidence 65 Patents Covering 65 Ups Ante 65 Antitrust Violations 65 Restate Results 65 Suit Alleges 65 1Q Loss Narrows 65 Consummates 65 Universal Shelf Registration 65 Partial Settlement 65 LLP Investigating 65 Lawsuit Filed Against 65 Earns Milestone Payment 65 Provides Preliminary 65 Stock Buyback 65 Trims Loss 65 Boosts Buyback 65 Settles Patent Suit 65 Withdraws Proposal 65 First Patient Treated 65 Announces Effective Date 65 Strengthens Position 65 Restate Financial 65 Sexual Harassment Case 65 Files Amended Complaint 65 Copyright Infringement Lawsuit 65 Wrongful Death Case 65 Mylan Receives Approval 65 Receives Clearance 65 Updates Guidance 65 Amplifies 65 Court Throws Out 65 Unveils Next Generation 65 Restates Earnings 65 Q2 Profit Soars 65 Introduces Next Generation 65 Files Patent Suit 65 Settle Dispute 65 Q1 Profit Soars 65 Twersky LLP Announces 65 Finalizes Acquisition 65 Announces License Agreement 65 Annual Meeting Date 65 Files Antitrust Lawsuit 65 Upholds Ruling 65 Receives Notice 65 Lawsuit Alleges 65 Fee Dispute 65 Files Preliminary Proxy 65 Osteoporosis Drug 65 Trial Nears 65 Spins Off 65 Decision Upholding 65 Lawsuit Dismissal 65 Losses Narrow 65 4Q Profit Soars 65 Dismiss Charges 65 Wider Loss 65 Unveils Expanded 65 Judge Clears Way 65 Files Suit Against 65 Lowers Outlook 65 Cross Licensing Agreement 65 Stockholders Approve Merger 65 Jury Decides 65 Announces Effectiveness 65 Reaches Settlement 65 Reaches Tentative Settlement 65 Settles Lawsuit 65 Withdraws Application 65 Lung Cancer Drug 65 Punitive Damages 65 Fraud Suit Against 65 Expand Collaboration 65 File Sharing Case 65 Judge Upholds 65 3Q Profit Plunges 65 Proposed Buyout 65 Commercializes 65 Court Dismisses Lawsuit 65 Q3 Profit Drops 65 Posts Wider 65 Found Liable 65 Complete Merger 65 Favorable Decision 65 Order Approving 65 Filed Against 65 Reaffirms FY# Guidance 65 Seeks Damages 65 Initiates Enrollment 65 Validates 65 Temporary Injunction 65 Suit Alleging 65 Drug Fails 65 Nanophase Announces 65 Stockholders Approve Acquisition 65 Cholesterol Drug 65 Files Trademark 65 Infringe 65 Reverses Loss 65 Announcement Regarding 65 Ruling Favors 65 #cv# [003] 65 Buy Privately Held 65 Refile 65 Key Milestones 65 Receives Complete Response 65 Urges Shareholders 65 Q1 Profit Drops 65 Preliminary Injunction 65 Court Reverses Ruling 65 Signs License Agreement 65 Dismiss Suit 65 Announce Merger Agreement 65 FDA Approvals 65 Q4 Profit Declines 65 Blood Thinner 65 Q2 Profit Drops 65 Profit Dips 65 Expanded Indication 65 Has Filed 65 Flamel Technologies Announces 65 Q4 Profit Soars 65 Not Liable 65 Shareholder Vote 65 1Q Profit Falls 65 Discrimination Suit 65 Schizophrenia Drug 65 Unveils Latest 65 Expands Capabilities 65 Appeals Affirms 65 Acknowledges Receipt 65 Settles Lawsuit Against 65 Issues Clarification 64 Above Estimates 64 Appeals Upholds 64 Refocuses 64 Resolves Dispute 64 NASDAQ Delisting Notice 64 Boosts Outlook 64 Terminates Agreement 64 Q3 Profit Surges 64 Receives Certification 64 TriCo Bancshares Announces 64 Posts Smaller 64 Wrongful Death Lawsuit Filed 64 Raises Guidance 64 Receives Notice From 64 Extends Collaboration 64 NexMed Receives 64 Faces Delisting 64 Generic Versions 64 Goldfarb Branham Law Firm 64 #cv# [001] 64 Pending Merger 64 Initiates Clinical Trial 64 Delivers Next Generation 64 Issues Guidance 64 Achieves Positive 64 Buyout Talks 64 Weight Loss Drug 64 Reports Significantly Improved 64 Resolves Litigation 64 Q3 Profit Soars 64 Net Loss Narrows 64 Host Teleconference 64 Age Bias 64 Announce Collaboration Agreement 64 Submits Supplemental 64 Rape Conviction 64 Posts 1Q 64 Q4 Adj 64 Court Tosses 64 Announces Restatement 64 Hears Arguments 64 Submits Revised 64 NDA Submission 64 Shareholders Approve Merger Agreement 64 Milberg Weiss Announces 64 Demonstrates Commitment 64 Waiver Request 64 Wizzard Software Announces 64 Can Proceed 64 False Marking 64 Files Shelf Registration Statement 64 Appeal Denied 64 Net Loss Widens 64 Migraine Drug 64 Urges Stockholders 64 Milestone Payments 64 Broadens Scope 64 Supplemental Biologics License Application 64 2Q Loss Narrows 64 Restructures Operations 64 Patented Technology 64 Travolta Extortion Case 64 Share Buyback 64 Civil Suit 64 Review Strategic Alternatives 64 Stock Tumbles 64 Anounces 64 Drops Suit 64 Formalizes 64 Broadens Its 64 Resubmit 64 Share Buybacks 64 Buyback Plan 64 Completes Previously Announced 64 ENFORCEMENT PROCEEDINGS 64 FDA Okays 64 Extends Leadership 64 Acquire Privately Held 64 Director Shareholding 64 Takes Plea 64 Unveils Revolutionary 64 Host Webcast 64 Posts 2Q Loss 64 Shares Surge 64 Discrimination Claims 64 Introduces Revolutionary 64 Completes Reorganization 64 Abuse Claim 64 Applauds FCC 64 Losses Widen 64 Seek Dismissal 64 Shares Climb 64 Nasdaq Deficiency Notice 64 Order Granting 64 non infringement invalidity 64 Meets Estimates 64 Q1 Profit Plunges 64 Appeal Ruling 64 Loses Lawsuit 64 Secures Financing 64 Options Backdating 64 Enhances User Experience 64 Mutually Agree 64 Cuts Costs 64 Jury Tampering 64 Invoke Fifth Amendment 64 Q1 Profit Declines 64 Expands Scope 64 Completes Divestiture 64 Denies Bid 64 Drug Candidate 64 Countersues 64 Tax Evasion Case 64 PDUFA Date 64 Announce Availability 64 Narrower Loss 64 Slashes Price 64 Posts Strong 64 Announces Adjournment 64 Settle Lawsuit 64 4Q Profit Down 64 Demands Immediate 64 Contract Dispute 64 Issues Resolved 64 Obtains Approval 64 Wins Injunction 64 Initiates Phase II 64 4Q Loss 64 Judge Overturns 64 Buyout Rumors 64 Q2 Profit Declines 64 Enables Easy 64 Stem Cell Patents 64 Sets Precedent 64 Ruling Upheld 64 Subsidiary Files 64 Tortious Interference 64 Taglich Brothers Initiates Coverage 64 Lawsuit Filed Over 64 Copyright Infringement 64 Hear Arguments 64 reaffirms FY# outlook 64 Confirms Filing 64 Posts Narrower Loss 64 Slashes Guidance 63 Same Sex Divorce 63 Announce Definitive Agreement 63 Aquires 63 Commences Mailing 63 ENFORCEMENT PROCEEDINGS SEC 63 Unveil Next Generation 63 Maximize Shareholder Value 63 Settle Suit 63 Nasdaq Delisting Notification 63 Judge Refuses 63 Announces Filing 63 Provides Updated 63 Completes Transition 63 Court Reinstates 63 Below Estimates 63 Witness Tampering 63 Launches Generic Version 63 Completes Merger With 63 Announce Filing 63 Significantly Increases 63 Seeks Approval 63 Announces Issuance 63 Remands 63 Court Hears Arguments 63 Q3 Profit Plunges 63 Proposed Rule Changes 63 BioSante Pharmaceuticals Announces 63 Discrimination Suit Against 63 Posts 3Q 63 Q4 Profit Slips 63 Commence Tender Offer 63 Announce Initiation 63 1Q Profit Down 63 Inhaled Insulin 63 DOR BioPharma Announces 63 Wider Than Expected 63 Finalize Agreement 63 Flagship Product 63 Deliver Next Generation 63 Conspiracy Charges 63 Files Shelf Registration 63 Q1 Profit Dips 63 Enjoin 63 Neutral Analyst Blog 63 Commences Consent Solicitation 63 Announces Successful Completion 63 Demonstrates Significant 63 Announces Discontinuation 63 Lawsuit Settlement 63 Introduce Next Generation 63 4Q Profit Falls 63 First Patient Enrolled 63 3Q Loss 63 1Q Loss 63 Announce Licensing 63 Announces Organizational Changes 63 Jury Selection Starts 63 Collaborates With 63 Technicals Showing Bullish 63 Judge Declares Mistrial 63 Summary Judgment Motion 63 Nearly Triples 63 OKs Buyback 63 Action Suit Filed 63 Settle Fraud 63 4Q Profit Jumps 63 Remains Neutral 63 Resolve Dispute 63 Gene Variants 63 IND Application 63 Files Resale 63 Below Consensus 63 Delay Filing 63 Hip Implants 63 4Q Profit Slips 63 Unveils Innovative 63 Q4 Profit Decreases 63 Has Spiked 63 Q3 Profit Declines 63 Withdraws Offer 63 Subsidiary Enters 63 Stock Option Backdating 63 Files Formal 63 Case Dismissed 63 Authorizes Additional 63 Request Denied 63 Closes Acquisition Of 63 Trial Halted 63 Exec Pleads Guilty 63 Completes Purchase Of 63 Q1 Profit Slips 63 Restates 63 Eliminates Need 63 Psoriasis Drug 63 Summary Judgment Motions 63 3rd Quarter Results 63 Lowers FY# Outlook 63 Halts Sale 63 Inks Licensing Deal 63 Nears Settlement 63 Profit Exceeds Estimates 63 Forecast Quick Facts 63 Stock Buyback Plan 63 Commences Tender Offer 63 Submits IND 63 4Q Loss Narrows 63 Beats Views 63 Case Settled 63 Expands Portfolio 63 Revises FY# Guidance 63 TiVo Posts Narrower 63 Competition G.1 63 Sex Discrimination Case 63 Submits Biologics License Application 63 Sinks Lower 63 3Q Profit Drops 63 Misses Views 63 Revises Guidance 63 Court Overturns 63 3Q Profit Falls 63 Feds Seek 63 Margin Expansion 63 Acquire Controlling Interest 63 Completes Integration 63 Reacquires 63 Sodomy Case 63 Initiates Dosing 63 Charges Brought 63 Partial Summary Judgment 63 Jury Finds 63 Issues Shareholder 63 Obscenity Case 63 Boosts Dividend 63 Dropped Against 63 Reaches Settlement With 63 Lifts FY# Guidance 63 Largest Shareholder 63 Receives Funding 63 Updates Status 63 Exclusive License 63 Creditor Protection 63 Enters Into Settlement Agreement 63 Manslaughter Charge 63 Q3 Profit Jumps 63 Tossed Out 63 Brain Damaged Woman 63 Generic Version Of 63 Extend Partnership 63 Private Equity Buyout 63 Discrimination Lawsuit Against 63 Sell Itself 63 Malpractice Lawsuit 63 Sweetens Bid 63 Harassment Case 63 Granted Early Termination 63 3Q Profit Rises 63 Updates Shareholders 63 Confirmatory Phase 63 Antitrust Clearance 63 Receives Orphan Drug 63 Court Quashes 63 Raises Outlook 63 Presents Preclinical Data 63 2Q Profit Down 63 FY# Guidance 63 Schiavo Feeding Tube 63 Upholds 63 Extend Relationship 63 Stockholder Vote 63 Dramatically Expands 63 Directors Authorizes 63 Inks License 63 Revises Third Quarter 63 Murder Conviction 63 Initiates Voluntary Recall 63 Announces Termination 63 Announces Enhancements 63 Successfully Completes Acquisition 63 Pregnant Woman Death 63 1Q Profit Slips 63 Posts Loss 63 Cholesterol Lowering Drug 63 Buyout Offer 63 Receives Tentative Approval 63 Merge Healthcare Announces 63 Adopts Stockholder Rights 63 Acquisition Proposal 63 Reveals Receipt 63 Announces Intention 63 Settles FTC 63 Hikes Dividend 63 Signs Merger Agreement 63 Lawsuits Against 63 Jury Deadlocked 63 Confirms Commitment 63 Restates Results 63 Resubmits 63 Anemia Drugs 63 Loses Bid 63 Announces Profitable 63 Terminates Contract 63 Confirms Guidance 63 Announces Receipt 63 Starts Shipping 63 Libel Lawsuit 63 Announces Initiation 63 Provides Unprecedented 63 IND Filing 63 Increases Share Repurchase 63 Drug Shows Promise 63 Conviction Overturned 63 Quadruples 62 Subsidiary Receives 62 FDA Warns 62 Canaccord Genuity Reiterates Buy 62 Wrongful Death Lawsuit 62 Further Strengthens 62 Appeal Upholds 62 Q3 Profit Decreases 62 Earnings Cheat Sheet 62 Revenues Decline 62 Suit Filed Against 62 Receives Confirmation 62 Nasdaq Minimum Bid 62 Shelf Registration 62 2Q Profit Surges 62 Obtains Interim 62 Jury Mulls 62 Generic Lovenox 62 Introduces Innovative 62 Receives Notice Regarding 62 4Q Profit Drops 62 Silicone Breast Implants 62 Spins Out 62 2Q Profit 62 Exec Bonuses 62 Successfully Concludes 62 Previously Announced 62 Finalizes Purchase 62 Deliver Breakthrough 62 Rejects Appeal 62 Completes Transaction 62 Raises Bid 62 Estimate Analyst Blog 62 Fistel LLC Announces 62 Announce Collaboration 62 Purchases Moore Microprocessor 62 Announce Successful Completion 62 Damages Claim 62 Subsidiary Wins 62 Launches Unique 62 Shareholders Approve Acquisition 62 Suit Claims 62 Earnings Postmortem 62 Execs Plead Guilty 62 Doubles Capacity 62 Patent Filings 62 Seeks Buyer 62 Judge Denies 62 Re Affirms 62 Lowers Forecast 62 Nasdaq Listing Requirements 62 Fortifies 62 Beats Expectations 62 Prevails 62 Develop Innovative 62 Cigarette Maker 62 Statement Regarding 62 Clinical Trial Results 62 Flavored Cigarettes 62 Action Filed Against 62 Accelerate Commercialization 62 Files Complaint Against 62 Drug Maker 62 Initiates Clinical Trials 62 Paternity Suit 62 Files Wrongful Death 62 Reports 4Q Loss 62 Faces Setback 62 Delivers Strong 62 Files Annual Report 62 Voluntarily Withdraws 62 Informal Inquiry 62 Begins Shipping 62 Jury Returns 62 Extends Offer 62 Judge Dismisses 62 Completes Sale Of 62 Exec Sees 62 Announce Merger 62 3Q Profit Up 62 FCC Approves 62 Closing Arguments Set 62 Libel Suit 62 Enhance Shareholder Value 62 Amends Merger Agreement 62 Achieves Record Revenue 62 Seeks Delay 62 Invalidate 62 Loss Shrinks 62 Receives Anticipated 62 AUDIO PROVIDED BY 62 Filing Status 62 Waiting Period 62 2nd Quarter Results 62 1st Quarter Results 62 Announces Publication 62 Surpasses Expectations 62 Announce Interoperability 62 Litigations 62 Piracy Lawsuits 62 Completes Redemption 62 Files Amicus Brief 62 Seek Shareholder Approval 62 Upcoming Deadline